The approval enables the company to immediately commence commercialisation of the RDN system in the US. Credit: Medtronic.

Medtronic has received approval from the US Food and Drug Administration (FDA) for its Symplicity Spyral renal denervation (RDN) system to treat hypertension.

The approval allows the company to commence commercialisation of the RDN system immediately, also known as the Symplicity blood pressure procedure.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The minimally invasive procedure is intended to deliver radiofrequency energy to nerves near the kidneys, which can become overactive and result in high blood pressure.

Following sedation, the doctor places a single thin tube into the artery that goes to the kidney.

After inserting the tube, the doctor administers energy to the system to calm the extra activity of the nerves linked to the kidney.

Later, the tube will be taken out without leaving any implant behind. 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

While presently restricted to investigational use in China, Japan and Canada, the RDN system has received commercial approval in over 70 countries globally.

Medtronic Cardiovascular Portfolio’s Coronary and Renal Denervation business president and senior vice-president Jason Weidman said: “High blood pressure is a global health issue and patients need more options to manage their blood pressure.

“The approval of the Symplicity blood pressure procedure represents a significant milestone for physicians and patients in the treatment of hypertension.”

Last month, Medtronic obtained FDA approval for its Aurora EV-ICD MRI SureScan extravascular implantable cardioverter-defibrillator and Epsila EV MRI SureScan defibrillation lead for the treatment of fast heart rhythms that may cause sudden cardiac arrest.